Street Calls of the Week

Here is your Street Calls of the Week for the week of Sep. 21–25, 2026 — five days, five rating changes, each the most market-moving upgrade or downgrade of its session.

Monday, Sep. 22 — UBS pulls the plug on PG&E

The Call: UBS downgraded PG&E Corp (PCG) from Buy to Neutral, slashing its price target by 26% — from $19 down to $14.

Why it moved: This wasn’t a routine trim. UBS analyst Gregg Orrill flagged a compounding sequence of bad news: PG&E’s decision to rescind its long-term EPS growth rate guidance alongside a strategic review announcement on Sep. 2, and — crucially — the growing probability that California’s wildfire liability reform dies in committee this year. Governor Newsom, rather than convening a special session on wildfires, has pivoted to AI regulation. That killed the regulatory catalyst the bull case depended on.

UBS cut its long-term EPS growth assumption from 9.0% to 8.5%, compounding a $2 billion capex deferral through 2027–2030. Add tax-loss selling pressure and a rising-rate environment, and the stock had nowhere to hide. PG&E Corp (PCG) was already trading at $12.88 at the time of the downgrade — already below the old $19 price target, suggesting the market had started pricing in the problems before the analyst caught up.

The Bigger Picture: When a utility stock trades below the prior analyst target before a downgrade, it is often a sign the Street has been slow. The new $14 target reflects a 49% discount to peer P/E on 2028 estimates — a deeply defensive valuation with meaningful execution risk attached.

(Sep. 23, 2026)

Tuesday, Sep. 23 — HSBC cuts Netflix loose

The Call: HSBC analyst Mohammed Khallouf downgraded Netflix (NFLX) from Buy to Hold, cutting his price target from $96 to $76 — a 21% reduction — on intensifying competition from YouTube and a content-spending burden expected to compress 2027–2028 earnings. The stock slid 2.0% in morning trading on the downgrade.

Why it moved: This is the second major downgrade in a week. Wells Fargo’s Steven Cahall had already taken NFLX to Underweight (PT: $57) just days earlier on Sep. 18, citing an estimated 8% decline in viewing time per subscriber per day versus the first half of 2023 — and a projected 21% YoY drop in hours watched from the platform’s top 100 original titles. That call had already cost the stock roughly 5%.

HSBC’s follow-on downgrade extended the pain. The compounding of two major sell-side moves in five trading days signals genuine analyst community concern — not a single outlier. Meanwhile, a new Ipsos survey found 39% of Americans canceled at least one streaming subscription in the six months through mid-September, up from 29% in March. Analysts have labeled this phenomenon "streamflation."

The Bigger Picture: The streaming narrative has broken in both directions — engagement metrics are deteriorating while costs are rising. With Netflix (NFLX) closing the week at $71.15 (as of Sep. 25 close, 3:59 PM EDT), down 41.23% over the past year, the stock is repricing from growth premium to something more prosaic.

(Sep. 22, 2026)

Wednesday, Sep. 24 — Rothschild Redburn calls time on Moderna’s valuation

The Call: Rothschild Redburn downgraded Moderna (MRNA) from Neutral to Sell, setting a price target of just $81 — against a stock trading near $195 at the time. That implies roughly 58% downside from where shares stood.

Why it moved: Rothschild Redburn’s bearish thesis centers squarely on valuation: Moderna (MRNA) has been one of the year’s notable performers, up +712% over the past 12 months and +567% year-to-date, fueled by melanoma trial data and intismeran platform excitement. The Sell call — arriving the same week that Argus upgraded the stock to Buy (PT: $180) and Wolfe Research upgraded to Peerperform — turns this into a full-blown street debate.

When three separate rating actions point in two different directions simultaneously, it typically signals one thing: a binary catalyst approaching. In Moderna’s case, Phase III melanoma trial results are the live wire, with Argus and Wolfe betting on regulatory approval of the intismeran adjuvant platform and Rothschild Redburn saying the market has already priced in perfection.

The Bigger Picture: Moderna (MRNA) closed Friday at $198.88 (as of Sep. 25 close, 3:59 PM EDT), hitting a 52-week high of $202.67 during the session. The stock is holding above the Sell call, for now. But a $81 target vs. $199 price is the widest bull-bear spread on the Street this week — tread carefully.

(Sep. 25, 2026)

Thursday, Sep. 24 — HSBC downgrades BMW as China keeps getting worse

The Call: HSBC downgraded Bayerische Motoren Werke AG (BMW) from Buy to Hold, cutting its price target to €69 from €71, citing a China business deteriorating faster than previously modeled. Bayerische Motoren Werke AG (BMW) shares fell 2.5% on the session.

Why it moved: HSBC had upgraded BMW in July following the company’s profit warning — a classic "bad news is in the price" call. That thesis has now unraveled. The bank now expects China sales to fall roughly 25% year-over-year in 2026, worse than its prior 20% estimate, followed by a further 4% decline in 2027. Local Chinese premium brands — having grown 15% year-to-date — are outcompeting German names whose combined volumes (Audi, BMW, Mercedes-Benz) are down 22% YTD.

HSBC cut its 2027 and 2028 BMW operating profit estimates by 16–20%, putting the firm 7–17% below consensus for both years. "The Germans need to close the content gap," HSBC wrote, "but in the meantime, local earnings for them [are] taking a severe hit."

The Bigger Picture: The German premium automaker trade is unwinding in real time. Rising raw material costs, restructuring charges, and a structural shift in Chinese consumer preferences toward domestic EV brands have created a headwind with no near-term reversal in sight. HSBC’s downgrade isn’t a cyclical caution — it’s a structural reassessment.

(Sep. 24, 2026)

Friday, Sep. 25 — Barclays upgrades Humana on Medicare Star ratings outlook

The Call: Barclays analyst Andrew Mok upgraded Humana (HUM) from Equal-weight to Overweight, lifting his price target to $515 from $407 — a $108 increase, implying 29% upside from Thursday’s close. The stock rose as much as 9% intraday on Friday, its biggest single-day gain since June, before settling at $397.93 (+4.63%) at the Sep. 25 close (3:59 PM EDT). That makes it the week’s single biggest rating-change price reaction.

Why it moved: The catalyst is laser-focused: Medicare Star ratings. Barclays lifted its probability that Humana’s critical H5216 contract — covering 2.4 million lives — will be upgraded to bonus status to 75%, from a lower prior estimate. The H5216 contract is the single most important element of the company’s 2028 EPS roadmap, worth approximately $1.5B of EBIT and $9 of EPS if it flips to bonus. The Star ratings release is expected around Oct. 8, 2026 — less than two weeks away.

Mok argued that Humana enters the 2028 ratings cycle "in a much stronger position than it did a year ago" — a meaningful qualitative shift for a name that has spent the better part of 18 months in the penalty box. With a 52-week low of $163.11 and now trading near $398, this is a stock that has staged a recovery of +127% over 6 months, but the Barclays call suggests the catalyst cycle isn’t done.

The Bigger Picture: Medicare Advantage is a binary game when it comes to Star ratings — you’re either in the bonus pool or you’re not, and the economic gap between the two is significant. If Barclays is right about H5216, the Oct. 8 release could be the next major re-rating event. If the contract stays below threshold, expect fast retracement. This is the highest-conviction, highest-stakes call of the week.

(Sep. 25, 2026)

The week in one line

Five calls, five stories — a utility trapped by politics, a streaming king losing subscribers, a biotech too hot for bears to touch, a German automaker losing China one quarter at a time, and a health insurer one government report away from an earnings inflection. Wall Street is not trading sectors this week; it is trading specific catalysts.